Insulet vs Teleflex
Insulet reported revenue of $2.7 billion in fiscal 2025, 1.4 times Teleflex's $2.0 billion in fiscal 2025. Insulet's revenue grew 30.7% in its latest year, and Teleflex's grew 17.2%. Insulet had an operating margin of 17.5%, against 5.9% at Teleflex. Free cash flow was $378 million at Insulet and $1 million at Teleflex.
Side by side
| Insulet | Teleflex | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2.7B | $2.0B |
| Revenue growth | 30.7% | 17.2% |
| Revenue growth a year, last 5 years | 24.5% | −4.7% |
| Gross margin | 71.6% | 56.2% |
| Operating margin | 17.5% | 5.9% |
| Net margin | 9.1% | −45.5% |
| Free cash flow | $378M | $1M |
| Free cash flow margin | 13.9% | 0.1% |
| Return on capital | 20.4% | 2.1% |
| Net debt to EBITDA | 0.4x | 7.6x |
| Dividends and buybacks | $60M | $360M |
| Change in diluted share count | −2.7% | −5.0% |
| Last close | $146.51 | $150.87 |
| P/E at the last close | 23.9× | 18.3× |
| Insider trades, last 12 months | bought $2.9 million, sold $602,397 | — |
| Piotroski F-score | 7 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InsuletTeleflex
Operating margin
Percent of revenue
InsuletTeleflex
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InsuletTeleflex